Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20+
SponsorCity of Hope Medical Center
About this trial
Esophageal cancer remains a disease with a poor prognosis. Chemotherapy is an important part of its treatment, but there are cases in which chemotherapy is ineffective. The investigators aim to develop a model to predict the response to chemotherapy by DNA methylation of preoperative biopsy specimens to identify the chemotherapy ineffective group.
Eligibility criteria
Qualifiers
Patients who had histologically confirmed esophageal squamous cell carcinoma.
Patients who had undergone chemotherapy.
Patients receiving initial chemotherapy
Written informed consent following full study information is provided to the patient.
Disqualifiers
Patients for whom a preoperative biopsy sample cannot be obtained
Patients who cannot assess at 2 months later after chemotherapy.
Patients with multiple cancers.
Trial design
Treatments tested in this trial
- Fluoro Uracil
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov